New Patent Granted

HAMLET Pharma AB is pleased to announce the grant of US Patent No. 9,487,561 and the imminent grant on November 16th 2016 of European Patent No. 2,643,010. These patents, together with existing US Patent No. 9,085,643, provide protection for the important ‘second-generation’ peptide-based compounds, reported previously.

The Hamlet peptide complexes include key tumoricidal motifs within HAMLET. They are formed by peptides and oleic acid, and reproduce essential tumoricidal activities of HAMLET. The a1H peptide-oleate complex is therefore under active investigation as a novel therapeutic, for Phase II trials. Advantages include; I) easier to produce on a large-scale, with high levels of precision, suitable for GMP approval; II) lower cost than recombinant production of the entire HAMLET complex and III) significantly longer patent life.

The grant of these patents provides further recognition of the quality of the innovation being carried out by the HAMLET Pharma team.  

For more information, please contact

Catharina Svanborg, Chairman of the board, Hamlet Pharma, +46-709 42 65 49
Catharina.svanborg@med.lu.se

Mats Persson, CEO Hamlet Pharma, +46 705 17 67 57
mats.persson@hamletpharma.com 

About Hamlet Pharma

Hamlet Pharma AB owns and develops a new technology to kill cancer cells without harming healthy tissues. The HAMLET technology is focused around the HAMLET family of tumoricidal protein-lipid complexes, formed by naturally occurring molecules from human milk and extended to include recombinant variants of the natural substance. HAMLET has validated therapeutic efficacy in clinical studies and animal models, and in many different cellular models of human cancer. HAMLET will now be developed further for Phase II clinical trials, to verify the positive proof of concept studies. Hamlet Pharma AB shares are listed at AktieTorget. HAMLET is an abbreviation for Human Alpha-lactalbumin Made LEthal to Tumor cells.